EFFICACY OF AS-NEEDED INTRAVITREAL INJECTION COMPARED TO 3-MONTHLY LOADING OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR BRANCH RETINAL VEIN OCCLUSION

TA KHAN; S NAVEED; S RIAZ; S ANJUM; F NAUREEN; A HASSAN

doi:10.54112/bcsrj.v2024i1.1279

Authors

TA KHAN Department of Vitreoretina Al-Shifa Trust Eye Hospital Rawalpindi, Pakistan
S NAVEED Department of Vitreoretina Al-Shifa Trust Eye Hospital Rawalpindi, Pakistan
S RIAZ Alama Iqbal Medical College Jinnah hospital, Lahore, Pakistan
S ANJUM Al-Shifa Trust Eye Hospital Paeds Ophthalmology Rawalpindi, Pakistan
F NAUREEN Al-Shifa Trust Eye Hospital Paeds Ophthalmology Rawalpindi, Pakistan
A HASSAN Department of Vitreoretina Al-Shifa Trust Eye Hospital Rawalpindi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1279

Keywords:

Intravitreal Injection, Anti-VEGF, Branch Retinal Vein Occlusion, Efficacy, Loading Dose, Retinal Edema

Abstract

Branch retinal vein occlusion (BRVO) is a prevalent retinal vascular disorder and a significant cause of vision impairment, particularly in individuals over the age of 50. Objective: The basic aim of the study is to find the efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion. Methods: This prospective, comparative study was conducted at Al-Shifa Trust Eye Hospital, Rawalpindi from January 2024 to August 2024. A total of 55 patients diagnosed with BRVO were enrolled in the study. Results: Data were collected from 55 patients with a similar mean age of 53.45 ± 4.56 years and 52.4 ± 7.01 years, respectively. At baseline, the mean best-corrected visual acuity (BCVA) was comparable between the two groups (55.2 in Group A vs. 54.7 in Group B, p = 0.67), as was the mean central retinal thickness (CRT) (485.6 µm in Group A vs. 490.3 µm in Group B, p = 0.73). There were no statistically significant differences between the groups in these baseline characteristics. Conclusion: It is concluded that both the PRN-only and loading phase + PRN regimens are effective for treating BRVO, with the loading phase regimen providing slightly superior visual outcomes.

Downloads

Download data is not yet available.

References

Chung YR, Woo TK, Park HR, Lee K. Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion. Sci Rep. 2023 Jul 26;13(1):12068. doi: 10.1038/s41598-023-39303-2. PMID: 37495760; PMCID: PMC10372086

Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: Characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol. 2018;63:816–50. doi: 10.1016/j.survophthal.2018.04.005

Ang JL, et al. A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion. Eye (Lond). 2020;34:1770–96. doi: 10.1038/s41433-020-0861-9.

Singh R, Davoudi S, Ness S. Preventive factors, diagnosis, and management of injection-related endophthalmitis: A literature review. Graefes Arch Clin Exp Ophthalmol. 2022;260:2399–416. doi: 10.1007/s00417-022-05607-8.

Yin S, Cui Y, Jiao W, Zhao B. Potential prognostic indicators for patients with retinal vein occlusion. Front Med. 2022;9:839082. doi: 10.3389/fmed.2022.839082.

Tang W, Guo J, Xu G, Liu W, Chang Q. Three monthly injections versus one initial injection of ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion: 12-month results of a prospective randomized study. Ophthalmol Ther. 2022;11:2309–20. doi: 10.1007/s40123-022-00588-7.

Miwa Y, et al. Ranibizumab for macular edema after branch retinal vein occlusion: One initial injection versus three monthly injections. Retina. 2017;37:702–09. doi: 10.1097/IAE.0000000000001224.

Bayat AH, et al. Comparison of one and three initial monthly intravitreal ranibizumab injections in patients with macular edema secondary to branch retinal vein occlusion. Int J Ophthalmol. 2018;11:1534–38. doi: 10.18240/ijo.2018.09.17.

Nagino Y, et al. Comparison of one injection to three monthly injections of anti-VEGF agent for macular edema associated with branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2018;59:4281.

Tadayoni R, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124:1778–87. doi: 10.1016/j.ophtha.2017.06.027.

Okamoto M, Yamashita M, Sakamoto T, Ogata N. Choroidal blood flow and thickness as predictors for response to anti-vascular endothelial growth factor therapy in macular edema secondary to branch retinal vein occlusion. Retina. 2018;38:550–58. doi: 10.1097/IAE.0000000000001566.

Yamada R, et al. Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion. Jpn J Ophthalmol. 2015;59:389–93. doi: 10.1007/s10384-015-0412-2.

Suzuki M, et al. Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy. Graefes Arch Clin Exp Ophthalmol. 2020;258:49–56. doi: 10.1007/s00417-019-04495-9

Lee GW, Kang SW, Kang MC, Kim SJ, Kim YY. Associations with recurrence of macular edema in branch retinal vein occlusion after the discontinuation of anti-vascular endothelial growth factor. Retina. 2021;41:1892–900. doi: 10.1097/IAE.0000000000003118.

Yoo JH, Ahn J, Oh J, Cha J, Kim SW. Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection. Br J Ophthalmol. 2017;101:1334–39. doi: 10.1136/bjophthalmol-2016-309749.

Jang JH, Kim YC, Shin JP. Correlation between macular edema recurrence and macular capillary network destruction in branch retinal vein occlusion. BMC Ophthalmol. 2020;20:341. doi: 10.1186/s12886-020-01611-w.

Choi KE, Yun C, Cha J, Kim SW. OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion. Sci Rep. 2019;9:14153. doi: 10.1038/s41598-019-50637-8.

Moon BG, Cho AR, Kim YN, Kim JG. Predictors of refractory macular edema after branch retinal vein occlusion following intravitreal bevacizumab. Retina. 2018;38:1166–74. doi: 10.1097/IAE.0000000000001674.

Ogura Y, et al. Current practice in the management of branch retinal vein occlusion in Japan: Survey results of retina specialists in Japan. Jpn J Ophthalmol. 2019;63:365–73. doi: 10.1007/s10384-019-00685-4.

Lamminsalo M, Urtti A, Ranta VP. Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data. Exp Eye Res. 2022;222:109162. doi: 10.1016/j.exer.2022.109